Syros to Present at Upcoming Investor Conferences in September
09/07/2021 - 08:00 AM
CAMBRIDGE, Mass. --(BUSINESS WIRE)--
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian , M.D., will present a corporate overview at two upcoming investor conferences in September. Management will also be available for one-on-one meetings.
H.C Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13
7:00 a.m. ET .
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Wednesday, September 22
2:05 p.m. ET
To access the webcasts and subsequent archived recording of each presentation, please visit the Investors & Media section of the Syros website at www.syros.com . An archived replay of each webcast will be available for approximately 30 days following each presentation.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com : https://www.businesswire.com/news/home/20210907005049/en/
Media Contact:
Naomi Aoki
Syros Pharmaceuticals
naoki@syros.com
Investor Contact:
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
Source: Syros Pharmaceuticals
Syros Pharmaceuticals Inc.
SYRS Rankings
#4660 Ranked by Stock Gains
SYRS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About SYRS
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
